Inogen (NASDAQ:INGN) Stock Rating Reaffirmed by Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of Inogen (NASDAQ:INGNFree Report) in a report issued on Wednesday, Benzinga reports.

Separately, William Blair raised shares of Inogen from a market perform rating to an outperform rating in a report on Thursday, February 15th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, Inogen presently has a consensus rating of Hold and an average price target of $7.00.

Read Our Latest Research Report on Inogen

Inogen Price Performance

NASDAQ:INGN opened at $8.46 on Wednesday. The company has a market cap of $199.49 million, a price-to-earnings ratio of -2.04 and a beta of 1.10. Inogen has a 1 year low of $4.13 and a 1 year high of $11.98. The stock’s 50 day simple moving average is $7.18 and its two-hundred day simple moving average is $6.57.

Inogen (NASDAQ:INGNGet Free Report) last announced its quarterly earnings results on Tuesday, May 7th. The medical technology company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.14. Inogen had a negative net margin of 30.07% and a negative return on equity of 42.87%. The company had revenue of $78.03 million for the quarter, compared to analysts’ expectations of $73.67 million. During the same quarter in the previous year, the business posted ($0.63) earnings per share. Inogen’s quarterly revenue was up 8.1% on a year-over-year basis. As a group, analysts anticipate that Inogen will post -2.47 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Inogen by 4.9% in the first quarter. Vanguard Group Inc. now owns 1,424,026 shares of the medical technology company’s stock valued at $11,492,000 after acquiring an additional 65,954 shares during the period. Tocqueville Asset Management L.P. grew its holdings in Inogen by 27.3% during the 1st quarter. Tocqueville Asset Management L.P. now owns 93,350 shares of the medical technology company’s stock valued at $753,000 after purchasing an additional 20,000 shares during the last quarter. Inspire Advisors LLC purchased a new stake in Inogen in the 1st quarter worth about $255,000. Susquehanna Fundamental Investments LLC bought a new stake in Inogen in the first quarter worth about $81,000. Finally, Oppenheimer Asset Management Inc. purchased a new position in shares of Inogen during the first quarter valued at approximately $121,000. 89.94% of the stock is owned by hedge funds and other institutional investors.

About Inogen

(Get Free Report)

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Read More

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.